DSP-0509, a systemically available TLR7 agonist, exhibits combination effect with immune checkpoint blockade by activating anti-tumor immune effects
TLR7 is an innate immune receptor that recognizes single-stranded RNAs, and its activation leads to anti-tumor immune effects. Although it is the only approved TLR7 agonist in cancer therapy, imiquimod is allowed to be administered with topical formulation. Thus, systemic administrative TLR7 agonist...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-01-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1055671/full |
| _version_ | 1811175319209508864 |
|---|---|
| author | Yosuke Ota Yasuhiro Nagai Yuko Hirose Seiji Hori Erina Koga-Yamakawa Ken Eguchi Kentaro Sumida Masashi Murata Hiroki Umehara Setsuko Yamamoto |
| author_facet | Yosuke Ota Yasuhiro Nagai Yuko Hirose Seiji Hori Erina Koga-Yamakawa Ken Eguchi Kentaro Sumida Masashi Murata Hiroki Umehara Setsuko Yamamoto |
| author_sort | Yosuke Ota |
| collection | DOAJ |
| description | TLR7 is an innate immune receptor that recognizes single-stranded RNAs, and its activation leads to anti-tumor immune effects. Although it is the only approved TLR7 agonist in cancer therapy, imiquimod is allowed to be administered with topical formulation. Thus, systemic administrative TLR7 agonist is expected in terms of expanding applicable cancer types. Here, we demonstrated the identification and characterization of DSP-0509 as a novel small-molecule TLR7 agonist. DSP-0509 is designed to have unique physicochemical features that could be administered systemically with a short half-life. DSP-0509 activated bone marrow-derived dendritic cells (BMDCs) and induced inflammatory cytokines including type I interferons. In the LM8 tumor-bearing mouse model, DSP-0509 reduced tumor growth not only in subcutaneous primary lesions but also in lung metastatic lesions. DSP-0509 inhibited tumor growth in several syngeneic tumor-bearing mouse models. We found that the CD8+ T cell infiltration of tumor before treatment tended to be positively correlated with anti-tumor efficacy in several mouse tumor models. The combination of DSP-0509 with anti-PD-1 antibody significantly enhanced the tumor growth inhibition compared to each monotherapy in CT26 model mice. In addition, the effector memory T cells were expanded in both the peripheral blood and tumor, and rejection of tumor re-challenge occurred in the combination group. Moreover, synergistic anti-tumor efficacy and effector memory T cell upregulation were also observed for the combination with anti-CTLA-4 antibody. The analysis of the tumor-immune microenvironment by using the nCounter assay revealed that the combination of DSP-0509 with anti-PD-1 antibody enhanced infiltration by multiple immune cells including cytotoxic T cells. In addition, the T cell function pathway and antigen presentation pathway were activated in the combination group. We confirmed that DSP-0509 enhanced the anti-tumor immune effects of anti-PD-1 antibody by inducing type I interferons via activation of dendritic cells and even CTLs. In conclusion, we expect that DSP-0509, a new TLR7 agonist that synergistically induces anti-tumor effector memory T cells with immune checkpoint blockers (ICBs) and can be administered systemically, will be used in the treatment of multiple cancers. |
| first_indexed | 2024-04-10T19:35:09Z |
| format | Article |
| id | doaj.art-103bbd04cd954e7799b9a9439e8f176b |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-04-10T19:35:09Z |
| publishDate | 2023-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-103bbd04cd954e7799b9a9439e8f176b2023-01-30T07:18:18ZengFrontiers Media S.A.Frontiers in Immunology1664-32242023-01-011410.3389/fimmu.2023.10556711055671DSP-0509, a systemically available TLR7 agonist, exhibits combination effect with immune checkpoint blockade by activating anti-tumor immune effectsYosuke OtaYasuhiro NagaiYuko HiroseSeiji HoriErina Koga-YamakawaKen EguchiKentaro SumidaMasashi MurataHiroki UmeharaSetsuko YamamotoTLR7 is an innate immune receptor that recognizes single-stranded RNAs, and its activation leads to anti-tumor immune effects. Although it is the only approved TLR7 agonist in cancer therapy, imiquimod is allowed to be administered with topical formulation. Thus, systemic administrative TLR7 agonist is expected in terms of expanding applicable cancer types. Here, we demonstrated the identification and characterization of DSP-0509 as a novel small-molecule TLR7 agonist. DSP-0509 is designed to have unique physicochemical features that could be administered systemically with a short half-life. DSP-0509 activated bone marrow-derived dendritic cells (BMDCs) and induced inflammatory cytokines including type I interferons. In the LM8 tumor-bearing mouse model, DSP-0509 reduced tumor growth not only in subcutaneous primary lesions but also in lung metastatic lesions. DSP-0509 inhibited tumor growth in several syngeneic tumor-bearing mouse models. We found that the CD8+ T cell infiltration of tumor before treatment tended to be positively correlated with anti-tumor efficacy in several mouse tumor models. The combination of DSP-0509 with anti-PD-1 antibody significantly enhanced the tumor growth inhibition compared to each monotherapy in CT26 model mice. In addition, the effector memory T cells were expanded in both the peripheral blood and tumor, and rejection of tumor re-challenge occurred in the combination group. Moreover, synergistic anti-tumor efficacy and effector memory T cell upregulation were also observed for the combination with anti-CTLA-4 antibody. The analysis of the tumor-immune microenvironment by using the nCounter assay revealed that the combination of DSP-0509 with anti-PD-1 antibody enhanced infiltration by multiple immune cells including cytotoxic T cells. In addition, the T cell function pathway and antigen presentation pathway were activated in the combination group. We confirmed that DSP-0509 enhanced the anti-tumor immune effects of anti-PD-1 antibody by inducing type I interferons via activation of dendritic cells and even CTLs. In conclusion, we expect that DSP-0509, a new TLR7 agonist that synergistically induces anti-tumor effector memory T cells with immune checkpoint blockers (ICBs) and can be administered systemically, will be used in the treatment of multiple cancers.https://www.frontiersin.org/articles/10.3389/fimmu.2023.1055671/fullTLR7 agonistDSP-0509check point blockercombinationeffector memory T cell |
| spellingShingle | Yosuke Ota Yasuhiro Nagai Yuko Hirose Seiji Hori Erina Koga-Yamakawa Ken Eguchi Kentaro Sumida Masashi Murata Hiroki Umehara Setsuko Yamamoto DSP-0509, a systemically available TLR7 agonist, exhibits combination effect with immune checkpoint blockade by activating anti-tumor immune effects Frontiers in Immunology TLR7 agonist DSP-0509 check point blocker combination effector memory T cell |
| title | DSP-0509, a systemically available TLR7 agonist, exhibits combination effect with immune checkpoint blockade by activating anti-tumor immune effects |
| title_full | DSP-0509, a systemically available TLR7 agonist, exhibits combination effect with immune checkpoint blockade by activating anti-tumor immune effects |
| title_fullStr | DSP-0509, a systemically available TLR7 agonist, exhibits combination effect with immune checkpoint blockade by activating anti-tumor immune effects |
| title_full_unstemmed | DSP-0509, a systemically available TLR7 agonist, exhibits combination effect with immune checkpoint blockade by activating anti-tumor immune effects |
| title_short | DSP-0509, a systemically available TLR7 agonist, exhibits combination effect with immune checkpoint blockade by activating anti-tumor immune effects |
| title_sort | dsp 0509 a systemically available tlr7 agonist exhibits combination effect with immune checkpoint blockade by activating anti tumor immune effects |
| topic | TLR7 agonist DSP-0509 check point blocker combination effector memory T cell |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1055671/full |
| work_keys_str_mv | AT yosukeota dsp0509asystemicallyavailabletlr7agonistexhibitscombinationeffectwithimmunecheckpointblockadebyactivatingantitumorimmuneeffects AT yasuhironagai dsp0509asystemicallyavailabletlr7agonistexhibitscombinationeffectwithimmunecheckpointblockadebyactivatingantitumorimmuneeffects AT yukohirose dsp0509asystemicallyavailabletlr7agonistexhibitscombinationeffectwithimmunecheckpointblockadebyactivatingantitumorimmuneeffects AT seijihori dsp0509asystemicallyavailabletlr7agonistexhibitscombinationeffectwithimmunecheckpointblockadebyactivatingantitumorimmuneeffects AT erinakogayamakawa dsp0509asystemicallyavailabletlr7agonistexhibitscombinationeffectwithimmunecheckpointblockadebyactivatingantitumorimmuneeffects AT keneguchi dsp0509asystemicallyavailabletlr7agonistexhibitscombinationeffectwithimmunecheckpointblockadebyactivatingantitumorimmuneeffects AT kentarosumida dsp0509asystemicallyavailabletlr7agonistexhibitscombinationeffectwithimmunecheckpointblockadebyactivatingantitumorimmuneeffects AT masashimurata dsp0509asystemicallyavailabletlr7agonistexhibitscombinationeffectwithimmunecheckpointblockadebyactivatingantitumorimmuneeffects AT hirokiumehara dsp0509asystemicallyavailabletlr7agonistexhibitscombinationeffectwithimmunecheckpointblockadebyactivatingantitumorimmuneeffects AT setsukoyamamoto dsp0509asystemicallyavailabletlr7agonistexhibitscombinationeffectwithimmunecheckpointblockadebyactivatingantitumorimmuneeffects |